## **INDUSTRY PARTNERSHIP FUND (IPF):** HAVE A DIRECT IMPACT ON SOUTH CAROLINA

SCRA has allocated **substantial additional funding** in grants and investments with a particular focus on current Client Companies to assist them in navigating through these unprecedented times. Your contribution to the IPF helps to make this possible.

## Have an impact.

Make a difference. Contribute to the IPF today.

## BENEFITS OF CONTRIBUTING TO THE IPF

- It helps early-stage companies during this current crisis – especially those contributing to solving this situation. The IPF funds innovative companies, such as those highlighted on the right.
- It improves your cash flow. A check to the IPF can be submitted today but dated as late as December 1, 2020, preserving needed cash.
- It allows you to direct your tax dollars. A check written to the South Carolina Department of Revenue goes into the state's general fund. A check written to the IPF, which creates a dollar-for-dollar South Carolina tax credit, is directed to fuel our innovation economy. In particular, these funds assist our early-stage Client Companies.
- It is deductible as a business expense for federal tax purposes. SCRA provides numerous marketing and business development benefits to companies that contribute to the IPF, which support the treatment of IPF contributions as business expenses for federal tax purposes.
- It is simple to do. Make a check payable to "IPF" and send it to SCRA, P.O. Box 95, Columbia, SC 29202. Upon receipt, contributors receive a letter that acknowledges their contribution. When the 2020 tax return is filed, submit SC Form TC36 with the return. It is that easy!



SC Launch, Inc. Portfolio Company, ZVerse, is addressing the COVID-19 medical supply shortage with direct manufacturing, responding to the crisis by providing face shields and other medical supplies that are urgently

needed by the healthcare community.

SC Facilities tenant, Vikor Scientific, understands the importance of the detection of emerging pathogens like Coronavirus and has developed testing kits that not only detect COVID-19, but also over 40 pathogens known to cause respiratory illness.



S COV

SCRA Client Company, Elastrin Therapeutics, has demonstrated proof-of-concept for a patented therapeutic compound that may provide needed repair and restorative function to lungs that have been damaged by the COVID-19 virus.





Or contact John E. Sircy, Director of Finance and Administration, **803.733.9069**, **john.sircy@scra.org**